Joe Rogan Reveals Trump IMMEDIATELY Offered Him FDA Approval for Unbelievable New Treatment...
President Donald Trump issued an executive order accelerating federal research on ibogaine, a Schedule I psychedelic, to create FDA pathways for veteran mental‑health treatment. The order follows claims that ibogaine can address depression, PTSD and substance abuse, with the FDA expected to release research vouchers soon. In separate developments, an Iranian‑American businesswoman was arrested at LAX for allegedly brokering a $70 million drone and ammunition deal to Sudan, and Wisconsin animal‑rights activists confronted police with tear gas at a beagle breeding facility. The post also contains a paid promotion for Mode Mobile’s AI data‑economy offering.
Dasatinib and Quercetin as Senolytic May Cause Brain Damage
A March 2026 PNAS study shows that the senolytic combo dasatinib and quercetin (D+Q) triggers demyelination in the corpus callosum of aged mice. The researchers used intermittent oral doses of 5 mg/kg dasatinib and 50 mg/kg quercetin, identical to regimens linked to...
A Closer Look at Body Composition in Obesity Drug Trials
A new systematic review of 36 randomized controlled trials, published in Annals of Internal Medicine, reveals that obesity medications often cause a sizable loss of lean mass. In 65% of drug trials, more than a quarter of total weight loss...
Weekly Reads: Prasad Successor, Sammy Hagar Stem Cells, More on OSK Trial, Finnish Speaker Needed
Vinay Prasad is set to leave his role as head of the FDA's Center for Biologics Evaluation and Research (CBER within two weeks, prompting speculation about the agency’s future direction. A new flexible oversight framework for rare‑disease gene and cell therapies...
The Next Chemical Cage Has a Beautiful Door
President Biden signed an executive order fast‑tracking psychedelic drugs, granting the FDA priority vouchers for serotonin‑2A agonists. The move follows a public ceremony with Joe Rogan, RFK Jr., and FDA Commissioner Marty Makary, signaling a shift from traditional plant‑based use to pharmaceutical...
HSS Studies Contribute Early Evidence to Help Guide Emerging Perioperative Considerations for Patients Using GLP‑1 Medications
At the ASRA annual meeting, Hospital for Special Surgery researchers presented two studies on peri‑operative management of patients taking GLP‑1 agonists. A multicenter ultrasound assessment of 354 elective surgery patients found no statistically significant difference in full‑stomach incidence between GLP‑1...
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments
Compass Pathways welcomed the White House Executive Order aimed at speeding up research and access to psychedelic therapies for serious mental illness. The biotech highlighted its COMP360 synthetic psilocybin, which has delivered statistically significant results in two Phase 3 trials for...
INVITATION: Join Me for a Live Session on Personalised Drug Repurposing in Cancer Care
Amanda, the Metabolic Nutritionist, will co‑host a live conversation with author and metabolic oncology researcher Travis Christofferson on drug repurposing in precision oncology. The event, organized by Astron Health, will explore how approved medications can be matched to cancer patients...
Capitol Dispatch Weekend Digest
The Capitol Dispatch Weekend Digest reports several policy‑driven shifts affecting Connecticut and the nation. A Senate committee found that drug companies which secured pricing deals under the Trump administration later raised prices on unrelated medicines, while USDA data shows Connecticut’s...
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation...
Zai Lab unveiled preclinical data for ZL-1503, a bispecific antibody that blocks IL-13 and IL-31Rα, showing sustained itch suppression and inflammation reduction for up to 112 days after a single dose. The study demonstrated dose‑dependent efficacy across skin, lung, nasal...
GPT-Rosalind Lands: What OpenAI’s First Domain-Specific Life Sciences Model, the Codex Life Sciences Plugin & the Trusted Access Program Actually...
OpenAI unveiled GPT‑Rosalind on April 16, its first domain‑specific model built for life‑sciences tasks such as biochemistry, genomics, and protein engineering. Access is limited to a Trusted‑Access program that currently includes Amgen, Moderna, Thermo Fisher Scientific, the Allen Institute and...
Retatrutide - Possibly Better than Semaglutide B/C Lower Nausea/Side Effect Profile, but Higher Heart Rate
Retatrutide, a triple‑agonist peptide, is generating buzz for delivering dramatic weight loss at doses of 8‑12 mg, rivaling semaglutide while causing fewer nausea complaints. Early users note that appetite suppression diminishes after several weeks, yet the drug continues to support weight‑maintenance...
Hazel Szeto, SS-31 Peptide, the World's First FDA-Approved Mitochondria-Targeted Drug (Longevity Summit, 2025)
SS‑31 (elamipretide), the first FDA‑approved mitochondria‑targeted drug, is being promoted on TikTok as a vision enhancer, despite its approval only for a rare mitochondrial disease. Clinical data for age‑related macular degeneration (AMD) show the drug failed to meet endpoints, with...
Imeglimin. A New and Novel Drug Thats Better than Metformin
Imeglimin, a mitochondrial‑targeted antidiabetic agent, is emerging as a novel alternative to metformin. Pre‑clinical studies show it restores mitochondrial function in skeletal muscle and pancreatic β‑cells, enhancing insulin secretion and reducing oxidative stress. Phase‑3 trials report HbA1c reductions of 0.6‑0.9%...
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal...
Agenus presented Phase II data showing that a combination of botensilimab, balstilimab and the allo‑iNKT cell therapy agenT‑797 achieved a 77% disease‑control rate in PD‑1‑refractory gastroesophageal adenocarcinoma. Patients who received an induction cycle of agenT‑797 before the full regimen experienced median...
SAGA Diagnostics to Present New Pathlight™ MRD Data for Ovarian and Metastatic Breast Cancer at AACR 2026
SAGA Diagnostics will present two abstracts at AACR 2026 showcasing its Pathlight™ structural‑variant‑based circulating tumor DNA (ctDNA) assay. In metastatic breast cancer, the test achieved a 77% detection rate, with ultrasensitive reads predicting therapeutic response and preceding radiologic progression. In...
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer...
Zai Lab reported that its DLL3‑targeting ADC zocilurtatug pelitecan (Zoci) generated a 53.7% confirmed intracranial objective response rate (iORR) in extensive‑stage small‑cell lung cancer (ES‑SCLC) patients with brain metastases, rising to 62.5% at the 1.6 mg/kg dose. In a separate cohort...
Bringing AI-Driven Protein-Design Tools to Biologists Everywhere
OpenProtein.AI has launched a no‑code, web‑based platform that gives biologists instant access to powerful protein‑language models and design tools. The suite includes the PoET transformer and its newer PoET‑2 version, which delivers higher accuracy while using a fraction of the...
Anti-Amyloid Alzheimer’s Drugs Show Limited Benefit in Cochrane Review
A Cochrane review of 17 randomized trials involving 20,342 participants found that anti‑amyloid antibodies deliver little to no clinically meaningful improvement in memory, cognition, or dementia severity after roughly 18 months of treatment. The analysis also identified a markedly higher...
Industry Report: Advanced Therapy Market May Triple by 2030
Cardinal Health’s 2026 Advanced Therapy Report projects that the U.S. advanced therapy market will nearly triple, rising from 61 approved cell and gene treatments today to around 180 by 2030. The study, based on input from 160 physicians and administrators,...
Why Annex 21 Is an Important Commercial Risk Point in EU Market Entry
Charley Maxwell highlights that Annex 21, the EU GMP annex governing medicinal product imports, is more than a paperwork hurdle—it is a commercial risk point that can delay market entry. The annex requires the holder of a Manufacturing Import Authorisation and...
Inside Pharma's Revenue Engine: The Gross-to-Net Reckoning
Model N’s new podcast, Pricing & Policy with Model N, spotlights its annual state‑of‑revenue survey, revealing escalating gross‑to‑net (GTN) complexity across the pharmaceutical sector. Executives discuss how opaque PBM contracts, Medicaid program exits, and coordination‑of‑benefits failures erode net pricing. The conversation also...
Friday Hope: Palmitoylethanolamide (PEA): Inhibits Spike Entry, Reduces Proinflammatory Markers in COVID and Improves Symptomology in Long COVID
Recent peer‑reviewed studies demonstrate that palmitoylethanolamide (PEA), a naturally occurring lipid, can block SARS‑CoV‑2 spike protein entry, cut viral replication by roughly 70%, and lower key inflammatory biomarkers in acute COVID‑19 patients. A separate real‑world cohort shows PEA supplementation markedly...
Connecticut Judge Refuses to Hit Pause in Multistate Generic-Drug Antitrust Fight
A federal judge in Connecticut denied a request to pause the multistate antitrust lawsuit accusing generic‑drug manufacturers of price‑fixing. The ruling keeps the coordinated MDL active while settlement discussions continue, preserving litigation pressure on the defendants. The case is a...
Revolution Medicines' Daraxonrasib Cuts Pancreatic Cancer Death Risk by 60% – This Week in Biotech #96
Revolution Medicines announced Phase 3 RASolute 302 results for its oral RAS‑ON inhibitor daraxonrasib in second‑line metastatic pancreatic ductal adenocarcinoma. The trial reported a median overall survival of 13.2 months versus 6.7 months with standard chemotherapy, a hazard ratio of 0.40 and a 60%...
Prescription Drug Costs Soaring Under Trump Regime
A Senate Health, Education, Labor and Pensions Committee report, released by Sen. Bernie Sanders, reveals that drugmakers who signed price‑cut agreements with the Trump administration are simultaneously hiking prices on hundreds of other medications. New therapies now launch at an...
A Treasure Trove of Food for Thought From Julia Belluz
Julia Belluz’s New York Times essay examines GLP‑1 medicines as broad metabolic tools, not merely weight‑loss drugs. She outlines emerging cardiometabolic, brain‑health, and inflammation benefits while stressing that scientific proof lags behind rapid real‑world adoption. The piece gives weight to patient experiences...
Bringing New Delivery Methods to Treatments: Q&A with Richard Lowenthal
In March 2025 the FDA cleared ARS Pharmaceutical’s neffy, a needle‑free epinephrine nasal spray, marking the first major delivery innovation for the drug in over 35 years. CEO Richard Lowenthal explained that the spray eliminates needle anxiety, simplifies administration, and improves portability,...
The Turning Point for Oral Biologics: Q&A With Morten Graugaard
Orbis Medicines CEO Morten Graugaard says the FDA’s approval of Icotyde validates oral biologics as a viable drug class. He frames the decision as a proof point that macrocycle chemistry can translate biologic efficacy into a pill, but cautions that...
Enough Will They-Won’t They! FDA Pushes for Permanent Rare Pediatric Disease PRVs
The FDA’s FY2027 budget request asks Congress to make the Rare Pediatric Disease (RPD) Priority Review Voucher program permanent, ending its four‑year reauthorization cycle. A voucher lets sponsors shave FDA’s review time from ten to six months and can be...
Wellcome Leap Announces $2M Prize in $50M Quantum for Bio Challenge Program
Wellcome Leap announced that Algorithmiq earned the $2 million prize in its $50 million Quantum for Bio (Q4Bio) Challenge, marking the first end‑to‑end quantum‑classical workflow that simulates a photosensitizer drug for photodynamic cancer therapy. The program, launched in 2023, devoted $40 million to...
The Category 2 Peptide Unwind: How a Rogan Appearance, 14 Withdrawn Nominations & a July PCAC Docket Will Reprice the...
Kennedy’s appearance on The Joe Rogan Experience announced that roughly fourteen peptides could be re‑classified from FDA Category 2 back to Category 1, but no Federal Register rule has been issued yet. The announcement highlights a procedural path where nominators withdraw nominations,...
Pharmaceutical Executive Daily: Eli Lilly Releases Updated Safety Data for Foundayo
Eli Lilly has released topline safety results from its Phase III Achieve‑4 trial for Foundayo, addressing FDA‑requested evidence on cardiovascular, liver and gastric safety. The FDA’s post‑approval letter, issued on the day of approval, demanded trial data rather than observational studies. Concurrently,...
Planview and Ozmosi: Bringing AI-Powered Insight to Pharmaceutical Portfolio Decisions
Planview has partnered with Ozmosi to embed curated clinical‑trial and market intelligence into its portfolio management platform, enhancing AI‑driven decision‑making for pharmaceutical companies. The integration supplies real‑time external signals, allowing teams to benchmark assumptions, identify pipeline gaps, and monitor competitive...
ICER and Verdant Research Publish White Paper Examining FDA’s Accelerated Approval Pathway
The Institute for Clinical and Economic Review (ICER) and Verdant Research released a white paper urging reforms to the FDA’s accelerated approval pathway. The report highlights persistent issues such as surrogate‑endpoint uncertainty, delayed confirmatory trials, and opaque decision‑making. It proposes...
Acerand Therapeutics Updates the Phase I/II Study of ACE-106 (ACE-86225106), a Highly Selective and Potentially Best-in-Class PARP1 Inhibitor, in Advanced...
Acerand Therapeutics reported updated Phase I/II data for ACE‑106, a highly selective PARP1 inhibitor, in 57 heavily pre‑treated patients with advanced solid tumors. The drug showed no dose‑limiting toxicities and a safety profile that appears better than approved PARP inhibitors....
BMS-986482
Bristol Myers Squibb disclosed BMS-986482, a CRBN‑mediated degrader that targets the IKZF1‑4 transcription factors, at the ACS Spring 2026 First‑Time Disclosures session. The molecule entered a combined Phase 1/2 study aimed at patients with advanced solid tumors, marking BMS’s entry into...
Promega to Showcase Oncology Research Tools and Companion Diagnostics at AACR Annual Meeting 2026
Promega will showcase a suite of oncology‑focused tools at the AACR Annual Meeting in San Diego, including its Lumit® hKi‑67 proliferation assay, the TarSeer™ BRETSA™ target‑engagement platform, and FDA‑cleared OncoMate® MSI companion diagnostic. The company also unveiled pre‑configured automated nucleic‑acid...
Retatrutide Vs. Zepbound: How Does Lilly’s Next-Gen Obesity Drug Compare to Tirzepatide?
Eli Lilly’s investigational triple‑agonist retatrutide is delivering weight‑loss results that eclipse its approved dual‑agonist Zepbound (tirzepatide), with Phase III trials reporting up to 28.7% body‑weight reduction over 68 weeks and HbA1c drops of about 2.0%. Zepbound, already a blockbuster generating roughly...
CMS-0062-P Deep Dive: What the 2026 Interoperability and Prior Authorization for Drugs Proposed Rule Actually Means for Health Tech Investors...
CMS released the proposed rule CMS-0062-P on April 10, 2026, extending prior‑authorization interoperability to prescription drugs and mandating FHIR‑based API endpoint reporting across Medicare Advantage, Medicaid, CHIP and qualified health plans. The rule sets a comment deadline of June 15,...
AscentX Medical’s Dr. Sandhu on a New Approach to Treating GERD
AscentX Medical is developing G125, a regenerative injectable biomaterial designed to reinforce the lower esophageal sphincter in patients with gastroesophageal reflux disease (GERD). The platform delivers a biocompatible scaffold via a patented needle that integrates with tissue, promoting collagen growth...
Johnson & Johnson’s Experience Navigating The Commissioner’s National Priority Voucher Program
Johnson & Johnson’s hematology division secured FDA approval for a new multiple myeloma regimen—Tecvayli plus Darzalex Faspro—through the FDA Commissioner’s National Priority Voucher pilot. The approval came just 55 days after filing, marking the first blood‑cancer therapy to use the voucher...
FDA Looks East—Here’s What Industry Needs to Know
The FDA’s FY2027 budget proposes $2.5 million and five new full‑time staff to open foreign offices in Hanoi, Vietnam, and Tokyo, Japan, expanding its inspection footprint in East Asia. The request follows FY2026 congressional language urging permanent presence for unannounced inspections...
The FDA Just Rewrote the Rules for Gene Therapy Approval & Most Investors Haven’t Noticed Yet: The Plausible Mechanism Framework...
The FDA released two draft guidances in early 2026 that reshape gene‑therapy regulation. The Plausible Mechanism Framework (PMF) creates a formal pathway for individualized, ultra‑rare treatments, allowing single‑patient or tiny‑cohort data combined with mechanistic and natural‑history evidence to support marketing...
You're The Perfect Specimen
The blog post surveys a series of rapid‑changing trends, from GLP‑1 drugs turning into a massive, self‑directed health experiment to political leaders publicly disputing the Pope’s war doctrine. It highlights the cultural backlash against AI‑generated art, the surge of private‑equity...
Watching A Potential Big Pharma Buyout
A seasoned trader has flagged a small‑cap biotech that checks the key boxes big pharma seeks in an acquisition: late‑stage clinical validation, an imminent FDA decision, a multi‑billion‑dollar addressable market, and a cash‑rich balance sheet. The company’s lead asset is...
Organon’s VTAMA® (Tapinarof) Cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis
Organon announced that its steroid‑free VTAMA® (tapinarof) 1% cream received a strong, evidence‑based recommendation in the American Academy of Dermatology’s 2026 pediatric atopic dermatitis (AD) guidelines. The AAD highlighted VTAMA as the only topical treatment with high‑certainty evidence that is...
Pharma Finance Roundup: Platform Innovation Drives Biotech Investment Across Oncology and Immunology
This week’s biotech financing spotlighted platform‑driven innovation in oncology and immunology. Adcendo closed a $75 million Series C to expand its ADC pipeline, while Beeline Medicines launched with $300 million Series A to develop precision autoimmune therapies. Harbinger Health secured $100 million for its multi‑cancer...
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
Precision BioSciences received Clinical Trial Application approval to add sites in France and Romania to its global ELIMINATE‑B study of PBGENE‑HBV, an in‑vivo gene‑editing therapy for chronic hepatitis B. The expansion joins existing locations in the United Kingdom, Moldova, New Zealand, Hong Kong...
Homoharringtonine as a Senotherapeutic Drug
Researchers used a large‑scale drug‑repositioning screen to identify homoharringtonine (HHT), an FDA‑approved anti‑leukemic agent, as a potent senotherapeutic. In vitro, HHT selectively eliminated senescent pre‑adipocytes while sparing healthy cells. In male mice, HHT cleared senescent adipocytes, restored white‑adipose tissue function,...